posted on 2022-10-17, 18:17authored byCharles Blanluet, Diego A. Huyke, Ashwin Ramachandran, Alexandre S. Avaro, Juan G. Santiago
The specificity of CRISPR-Cas12 assays is attractive
for the detection
of single nucleotide polymorphisms (SNPs) implicated in, e.g., cancer and SARS-CoV-2 variants. Such assays often employ endpoint
measurements of SNP or wild type (WT) activated Cas12 trans-cleavage activity; however, the fundamental kinetic effects of SNP
versus WT activation remain unknown. We here show that endpoint-based
assays are limited by arbitrary experimental choices (like used reporter
concentration and assay duration) and work best for known target concentrations.
More importantly, we show that SNP (versus WT) activation results
in measurable kinetic shifts in the Cas12 trans-cleavage
substrate affinity (KM) and apparent catalytic
efficiency (kcat*/KM). To address
endpoint-based assay limitations, we then develop an assay based on
the quantification of Michaelis–Menten parameters and apply
this assay to a 20 base pair WT target of the SARS-CoV-2 E gene. We
find that the kcat*/KM measured for
WT is 130-fold greater than the lowest kcat*/KM among all 60 measured SNPs (compared to a 4.8-fold for
endpoint fluorescence of the same SNP). KM also offers a strong ability to distinguish SNPs, varies 27-fold
over all the cases, and, importantly, is insensitive to the target
concentration. Last, we point out trends among kinetic rates and SNP
base and location within the CRISPR-Cas12 targeted region.